List of Excipients in Branded Drug EQUALINE HEARTBURN PREVENTION

Generic Drugs Containing EQUALINE HEARTBURN PREVENTION

Company	Ingredient	NDC	Excipient
United Natural Foods Inc dba UNFI	famotidine	41163-001	CARNAUBA WAX
United Natural Foods Inc dba UNFI	famotidine	41163-001	CELLULOSE, MICROCRYSTALLINE
United Natural Foods Inc dba UNFI	famotidine	41163-001	CROSCARMELLOSE SODIUM
United Natural Foods Inc dba UNFI	famotidine	41163-001	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in EQUALINE HEARTBURN PREVENTION?

# Of NDCs	Excipient
3	CARNAUBA WAX
3	CELLULOSE, MICROCRYSTALLINE
2	CROSCARMELLOSE SODIUM
1	FERRIC OXIDE RED

Equaline Heartburn Prevention Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Equaline Heartburn Prevention is a private-label over-the-counter famotidine product used to prevent and relieve heartburn. Its commercial opportunity is driven less by active-ingredient exclusivity and more by formulation differentiation, manufacturing efficiency, package design, and retail-channel positioning. Famotidine is an established generic active ingredient regulated under the FDA OTC heartburn-prevention monograph, leaving limited scope for composition-of-matter protection but meaningful opportunities in dosage form, taste, disintegration, stability, and consumer convenience.[1]

What is Equaline Heartburn Prevention?

Equaline Heartburn Prevention is a store-brand famotidine product marketed for the prevention of heartburn associated with eating or drinking. Equaline products have appeared in multiple strengths and package configurations, including 10 mg and 20 mg tablets, depending on the retailer, NDC, and product generation.

Product characteristic	Commercial assessment
Brand	Equaline
Product category	OTC heartburn-prevention medicine
Active ingredient	Famotidine
Common strengths	10 mg and 20 mg
FDA pathway	OTC monograph product
Primary indication	Prevents and relieves heartburn
Likely dosage form	Immediate-release oral tablet
Prescription patent dependence	None for ordinary generic famotidine tablets
Orange Book relevance	Generally limited because OTC monograph products are not approved under an NDA
Main differentiation levers	Excipient system, tablet performance, packaging, price, retailer placement, and dosage-form convenience

The exact inactive-ingredient profile can vary by NDC, strength, manufacturer, and packaging configuration. Equaline is a private-label brand rather than a single globally standardized formulation.

What excipients are likely used in Equaline Heartburn Prevention tablets?

Immediate-release famotidine tablets generally require a compact, stable, rapidly disintegrating formulation. The likely excipient functions include filler, binder, disintegrant, lubricant, coating agent, and colorant.

Core excipient functions

Function	Common excipient options	Commercial purpose
Diluent or filler	Microcrystalline cellulose, lactose, dibasic calcium phosphate, starch	Controls tablet weight, flow, and compressibility
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Provides mechanical strength
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Promotes rapid tablet breakup
Lubricant	Magnesium stearate, stearic acid, sodium stearyl fumarate	Prevents sticking and improves ejection
Glidant	Colloidal silicon dioxide	Improves powder flow
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Improves swallowability, appearance, and handling
Colorant	Iron oxides, FD&C colors, titanium dioxide where permitted	Supports product identification
Sweetener or flavor	Sucralose, aspartame, mannitol, flavor systems	Relevant to chewable or orally disintegrating forms

Famotidine is a relatively low-dose active pharmaceutical ingredient in a tablet product. Excipients determine most of the dosage-form performance, including tablet hardness, friability, disintegration, dissolution, content uniformity, and physical stability.

What excipient strategy is commercially appropriate for famotidine?

The optimal strategy for a conventional Equaline tablet is a low-cost, robust direct-compression or dry-granulation platform that maintains rapid dissolution across manufacturing sites.

1. Use a high-functionality filler system

Microcrystalline cellulose is commercially attractive because it provides compressibility and supports direct compression. Dibasic calcium phosphate can improve tablet density and reduce tablet size, but it may produce a harder, slower-disintegrating tablet if the formulation is not balanced.

A co-processed filler can improve flow and compression while reducing process variability. The tradeoff is higher excipient cost and possible dependence on a specialty supplier.

2. Control disintegration without compromising hardness

Croscarmellose sodium and crospovidone are strong candidates for immediate-release famotidine tablets. Crospovidone can provide rapid wicking and is suitable for low-moisture processing. Croscarmellose sodium provides swelling-driven disintegration and is widely used in generic solid-dose products.

The formulation target should prioritize:

• Rapid tablet disintegration.
• Consistent dissolution through the labeled shelf life.
• Low friability.
• Adequate mechanical strength for high-speed packaging.
• Low sensitivity to lubricant overmixing.

Excess magnesium stearate or prolonged lubrication can reduce wetting and slow dissolution. Lubricant concentration and blend time are therefore important process-control variables.

3. Minimize moisture exposure

Famotidine formulations require appropriate control of water activity and humidity. Moisture can affect powder flow, tablet hardness, disintegration, coating integrity, and chemical stability.

A low-moisture excipient platform can reduce risk in humid distribution markets. Packaging should be selected with the formulation, not after it. High-barrier blister films or tightly sealed bottles may be justified where stability data show moisture sensitivity.

4. Consider taste and swallowability

Conventional coated tablets have limited taste exposure. Chewable and orally disintegrating products create a larger excipient challenge because famotidine can produce an unpleasant taste profile.

A chewable product may require:

• Mannitol or xylitol as a bulk sweetener.
• Sucralose or another high-intensity sweetener.
• Flavor masking.
• A saliva-compatible binder.
• A pleasant mouthfeel.
• Controlled tablet hardness to prevent excessive grittiness.

Taste masking can create the strongest excipient-related differentiation opportunity because it directly affects consumer acceptance and repeat purchase.

What formulations are protected by patents or exclusivity?

The ordinary Equaline famotidine tablet has limited patent-based protection. Famotidine's active ingredient is long genericized, and standard immediate-release tablets are widely available.

Potentially protectable subject matter includes:

1. Taste-masked famotidine compositions.
2. Orally disintegrating tablets.
3. Chewable tablets with defined disintegration and sensory properties.
4. Effervescent dosage forms.
5. Liquid formulations with improved stability.
6. Unit-dose packages with moisture-control features.
7. Combination products containing famotidine and another heartburn active.
8. Manufacturing processes that improve content uniformity or tablet robustness.
9. Specific excipient ratios linked to dissolution or stability results.
10. Pediatric formulations with improved palatability.

A patent strategy based only on familiar excipients at conventional concentrations is weak. Stronger claims require a defined formulation architecture and comparative data showing an unexpected technical effect, such as improved taste, stability, dissolution, or resistance to humidity.

Does Equaline Heartburn Prevention have Orange Book patents?

Equaline Heartburn Prevention is generally an OTC monograph product rather than an NDA product. The FDA Orange Book primarily lists approved drug products and associated patents or exclusivity for NDA and certain related applications. A private-label OTC monograph famotidine tablet ordinarily would not have a conventional Orange Book patent estate comparable to an NDA product.[2]

The relevant regulatory framework is the FDA OTC monograph for internal analgesic, antipyretic, and antirheumatic products? No. Famotidine heartburn-prevention products are regulated under the FDA OTC monograph covering antacid and acid-reducing products, including histamine-2 receptor antagonists. The product must comply with the applicable monograph conditions, labeling, dosage, active ingredient, and testing requirements.[1]

Are Paragraph IV challenges relevant to Equaline Heartburn Prevention?

Paragraph IV litigation is generally not the primary entry mechanism for an OTC monograph famotidine tablet. Paragraph IV certifications apply to abbreviated new drug applications that reference patents listed for an innovator NDA. A private-label OTC monograph product is normally commercialized without an ANDA-based patent certification process.

Generic prescription famotidine products have historically faced ordinary generic competition, but the commercial status of Equaline is different. The principal competitive risks are:

• Retailer replacement by another contract manufacturer.
• Private-label price competition.
• Supply interruption.
• Product recalls.
• Failure to meet monograph labeling or quality requirements.
• Loss of shelf placement.
• Consumer migration to omeprazole, esomeprazole, calcium carbonate, or alginate products.

When does Equaline Heartburn Prevention lose exclusivity?

Equaline Heartburn Prevention does not depend on a conventional new-drug exclusivity period. Famotidine is available through generic and OTC channels, so the product's economic exclusivity is retail-based rather than patent-based.

Exclusivity type	Status
New chemical entity exclusivity	Not applicable to generic famotidine
NDA exclusivity	Not generally applicable to the private-label OTC product
Orange Book patent exclusivity	Generally not applicable
OTC monograph market access	Available to compliant manufacturers
Retailer exclusivity	May exist through private-label supply or distribution contracts
Formulation patent exclusivity	Possible for a differentiated dosage form
Trademark exclusivity	Equaline brand rights may protect branding, not the medicine

A contract manufacturer can lose a private-label opportunity even when its formulation is technically compliant. Retail shelf economics and supply reliability often matter more than patent status.

What commercial opportunities exist for excipient-led differentiation?

Chewable famotidine

A chewable 10 mg or 20 mg product could target consumers who prefer not to swallow tablets. Excipient opportunities include mannitol-based compression, high-intensity sweeteners, flavor masking, and low-grit mouthfeel.

The product would compete with chewable antacids and other rapid-relief products. Its positioning would need to distinguish prevention from immediate neutralization of existing acid.

Orally disintegrating tablets

An orally disintegrating famotidine tablet could support convenience claims for consumers who have difficulty swallowing. The formulation would require rapid dispersion, acceptable taste, adequate mechanical strength, and packaging that limits moisture uptake.

Unit-dose blister packaging could create a stronger commercial proposition than a standard bottle. The downside is higher packaging cost and greater sensitivity to tablet friability.

Sugar-free and low-calorie products

A sugar-free chewable formulation could target diabetic consumers and consumers who avoid sucrose. Mannitol, sorbitol, xylitol, and nonnutritive sweeteners are possible components, but polyol loading must be controlled because excessive intake can cause gastrointestinal discomfort.

Pediatric-oriented products

A liquid or orally disintegrating formulation could serve pediatric patients where permitted by labeling and clinical-use requirements. The main technical barriers are palatability, preservative compatibility, dose accuracy, and age-appropriate labeling.

Combination products

Famotidine can be combined with antacid actives such as calcium carbonate or magnesium hydroxide. Combination products may improve consumer perception of rapid relief plus longer-duration acid reduction. They also increase formulation complexity, including compatibility, sedimentation, dose uniformity, and labeling requirements.

How strong is the patent estate for an Equaline famotidine formulation?

The patent strength depends on the product architecture.

Product type	Patent strength	Primary barrier
Standard immediate-release tablet	Low	Commodity formulation and established excipients
Film-coated tablet	Low	Limited technical differentiation
Chewable tablet	Moderate	Taste masking and sensory performance
Orally disintegrating tablet	Moderate	Disintegration, taste, and moisture protection
Stable liquid	Moderate	pH, preservative, and shelf-life performance
Multi-active combination	Moderate to high	Compatibility and defined release profile
Novel delivery system	Potentially high	Requires meaningful technical effect and development data

A formulation patent should claim measurable performance rather than only a list of ingredients. Useful claim parameters may include dissolution at defined time points, disintegration time, water activity, tablet hardness, friability, impurity levels, and stability after accelerated storage.

What manufacturing and intellectual-property barriers exist?

The main manufacturing barriers are operational rather than molecule-specific.

Manufacturing risks

• Famotidine content uniformity at low dose.
• Blend segregation during transfer and compression.
• Tablet capping or lamination.
• Lubricant-related dissolution slowdown.
• Coating variability.
• Moisture-driven stability loss.
• Flavor migration in chewable products.
• Cross-contamination controls in multi-product facilities.
• Packaging damage during high-speed bottling or blistering.

Intellectual-property risks

• Existing patents on taste-masking systems.
• Patents covering orally disintegrating matrices.
• Proprietary co-processed excipients.
• Combination-product patents.
• Trade secrets covering flavor systems and process parameters.
• Trademark and private-label supply agreements.
• Patent rights owned by excipient suppliers or formulation developers.

Freedom-to-operate analysis should cover the dosage form, excipient combination, manufacturing process, packaging system, and any combination active. The active ingredient alone is unlikely to create a meaningful barrier.

How does Equaline compare with competing heartburn products?

Product category	Active ingredient	Main consumer benefit	Excipient opportunity
Equaline Heartburn Prevention	Famotidine	Prevents and reduces acid-related heartburn	Low-cost tablet, chewable, ODT, sugar-free
Calcium carbonate antacid	Calcium carbonate	Rapid acid neutralization	Chewability, flavor, low chalkiness
Magnesium/aluminum antacid	Mineral salts	Rapid neutralization	Suspension stability, mouthfeel, portability
Omeprazole OTC	Omeprazole	Longer acid suppression	Delayed-release protection and capsule/tablet design
Esomeprazole OTC	Esomeprazole	Longer acid suppression	Enteric coating and stability
Famotidine-calcium carbonate combination	Multiple actives	Rapid relief plus acid reduction	Compatibility and dual-release performance

Famotidine occupies a middle position between immediate neutralizing antacids and longer-duration proton-pump inhibitors. Excipient differentiation is most commercially credible where it improves speed of use, portability, taste, or adherence.

What is the FDA regulatory status of Equaline Heartburn Prevention?

The product category is regulated as an OTC heartburn medicine. Compliance requirements include:

• Use of an allowed active ingredient and strength.
• Conformance with the applicable OTC monograph.
• Required Drug Facts labeling.
• Permitted indication and dosing language.
• Manufacturing under current good manufacturing practice requirements.
• Stability and quality testing.
• Appropriate packaging and tamper-evident presentation.
• Adverse-event and recall obligations.

A material change in dosage form, active combination, indication, or labeling may move the product outside the ordinary monograph pathway and require an FDA application or other regulatory review.

What is the revenue opportunity?

Equaline's revenue exposure is primarily a private-label and retail-channel question. The product competes on gross margin, unit velocity, shelf placement, and retailer exclusivity.

The most attractive opportunities are:

1. Higher-margin chewable and orally disintegrating products.
2. Multi-pack and travel-size packages.
3. Sugar-free products.
4. Retailer-exclusive formulations.
5. Combination products positioned for rapid relief and prevention.
6. Contract manufacturing platforms that can support multiple private-label brands.
7. High-barrier packaging for humid markets.
8. Pediatric or geriatric-friendly dosage forms where regulatory support is available.

A standard 10 mg or 20 mg tablet is unlikely to support premium pricing without packaging, brand, or retailer differentiation. A formulation with demonstrable taste, stability, or convenience advantages has stronger licensing potential.

Key Takeaways

• Equaline Heartburn Prevention is a private-label famotidine OTC product, generally available in 10 mg and 20 mg tablet formats.
• The product has limited active-ingredient or traditional NDA exclusivity.
• Excipient selection controls tablet robustness, disintegration, dissolution, moisture stability, and consumer acceptance.
• Conventional tablets offer low patent strength and limited premium pricing.
• Chewable, orally disintegrating, sugar-free, liquid, and combination formulations offer stronger commercial opportunities.
• The most defensible formulation patents require measurable technical advantages, not routine excipient combinations.
• Paragraph IV litigation and Orange Book patent disputes are generally less relevant than they are for NDA-backed prescription products.
• Retailer contracts, manufacturing reliability, packaging, and cost control are central to Equaline's commercial value.

FAQs

Can famotidine excipients be changed without a new FDA approval?

A change may be possible within the applicable OTC monograph and manufacturing requirements, but the finished product must remain compliant with labeling, quality, stability, and performance standards. A new dosage form or active combination may require a different regulatory pathway.

Is Equaline Heartburn Prevention interchangeable with Pepcid AC?

Products with the same active ingredient and strength may be therapeutically comparable when used according to their labels. Inactive ingredients, tablet characteristics, packaging, and labeling can differ.

Can an excipient combination support a patent for famotidine?

Yes, but routine use of known excipients is weak patent subject matter. Patent strength improves when the formulation delivers an unexpected result supported by comparative data.

Which excipients are most important for a famotidine chewable tablet?

The highest-impact components are the filler, sweetener, flavor-masking system, binder, lubricant, and disintegrant. Their interactions determine taste, mouthfeel, hardness, and disintegration.

Is a private-label famotidine product attractive for licensing?

A standard tablet has limited licensing value because multiple manufacturers can produce comparable products. A validated taste-masked, orally disintegrating, moisture-stable, or combination formulation has stronger licensing potential.

References

1. U.S. Food and Drug Administration. (2023). Over-the-counter monograph for heartburn prevention and treatment products. FDA.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
3. U.S. Food and Drug Administration. (2024). Drug Facts labeling for over-the-counter human drug products. FDA.
4. U.S. Food and Drug Administration. (2024). Current good manufacturing practice for finished pharmaceuticals, 21 C.F.R. Parts 210-211.
5. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. USP Convention.